The transforming growth factor-b (TGF-b receptor system has been implicated in the development of resistance to the growth-inhibitory eects of TGF-b. It has been reported that resistance to TGF-b correlates with inactivation of the TGF-b type II receptor (RII). In the present report, we examine the genetic changes in the TGF-b RII gene of human gastric cancer cell lines, SNU-5 and SNU-668, which we had previously reported to express truncated TGF-b RII transcripts. By independent PCR and Southern hybridization analysis of genomic DNA, we found that the genomic sequence of TGF-b RII is truncated after exon 2 in SNU-5 and after exon 3 in SNU-668. This was con®rmed by sequencing the TGF-b RII cDNA cloned from a SNU-5 cDNA library. Predicted TGF-b RII protein of SNU-5 cells based on sequencing data contains only a part of extracellular domain of TGF-b RII. We demonstrate that cotransfection of 3TP-Lux and wild type TGF-b RII restores the TGF-b responsiveness in SNU-5 cells, suggesting that genetic changes in the TGF-b RII gene of SNU-5 cells are responsible for the loss of sensitivity to TGF-b. This is the ®rst report demonstrating that truncation of the TGF-b RII gene is an alternative mechanism to inactivate the TGF-b signal transduction pathways.
Introduction
Transforming growth factor-b (TGF-b) is the prototypical multifunctional cytokine, playing an important role in regulating such fundamental cellular behavior as proliferation and dierentiation as well as systemic phenomena such as wound healing and immunity (Roberts and Sporn, 1990; MassagueÂ , 1990) . These multiple eects are dependent on a heteromeric cellsurface receptor complex which transduces the extracellular signal into intracellular messages (Lin and Moustakas, 1994; Wrana et al., 1994) .
Long suspected of being critically involved in the carcinogenesis pathway, the TGF-b ligand and receptor system has ®nally emerged as an important tumor suppressor responsible for restraining cell proliferation in an autocrine and paracrine fashion (Markowitz and Roberts, 1996; Kim and Kim, 1996) . Since the hypothesis that defects in the transforming growth factor b (TGF-b) receptor system might contribute to the development of resistance to the growth-inhibitory eects of TGF-b was ®rst introduced by Sporn and Roberts (1985) , correlations between resistance to growth inhibition by TGF-b and the lack of TGF-b receptor expression have been reported in a variety of dierent human cancer cell lines including gastric and colon cancer cells (Kimchi et al., 1988; Park et al., 1994; Sun et al., 1994; Markowitz et al., 1995; Kim and Kim, 1996) . It has furthermore been proposed that the development of such TGF-b resistance represents a signi®cant step in the process of carcinogenesis. The ®rst direct evidence that resistance to TGF-b can develop through mutation of a receptor gene came with the discovery that a majority of gastric cancer cell lines are resistant to the growth inhibitory eects of TGF-b and that this resistance correlates with gross structural defects of the TGF-b type II receptor (RII) gene (Park et al., 1994) . The TGF-b RII, in particular, is a favored target for mutations in cells possessing defective DNA repair mechanisms. These mutations inactivate the TGF-b RII, resulting in resistance to the growth inhibitory eect of TGF-b and increasingly malignant behavior of the aected cell population . A speci®c TGF-b RII mutation was subsequently associated with DNA microsatellite instability in hereditary nonpolyposis colon cancer (HNPCC; Markowtiz et al., 1995) and in gastric cancers . These mutations principally consist of frameshift mutations (insertion or deletion of one or two adenine bases) found clustered within a 10-basepair polyadenine repeat that is present in the coding region of the TGF-b RII. These mutations introduce early stop codons and encode truncated TGF-b RII (between 129 and 161 amino acids). Dierent TGF-b RII mutations have also been identi®ed in colon cancer and squamous cell cancers of the head and neck (Garrigue-Antar et al., 1995) .
Despite a strong correlation between TGF-b resistance and mutations of the TGF-b RII gene, examination of several TGF-b resistant gastric cancer cell lines has revealed multiple examples of tumors without mutations in either TGF-b RII and RI genes. Crosslinking assays have demonstrated decreased receptor levels, most consistently in TGF-b RII levels, in these cell lines despite the presence of intact wild type genes. Northern analysis has similarly demonstrated decreased levels of TGF-b RII mRNA.
These ®ndings also suggest that abnormalities in transcriptional regulation of the TGF-b RII is another mechanism to inactivate the TGF-b RII.
Results and discussion
Previously, we have observed several aberrant expression patterns of TGF-b type II receptor mRNA in human gastric cancer cells. Northern hybridization analysis detected short messages for TGF-b RII mRNA in the TGF-b non-responsive cell lines, SNU-5 and SNU-668, relative to the appropriate TGF-b RII mRNA size expressed in the TGF-b responsive SNU-16 cell line (Figure 1) . In most cells a single *5.5 kb message exists. However, the size of TGF-b RII message of SNU-5 is *1.2 kb. SNU-668 cells exhibited relatively lower message levels, and *1.2 kb and *3 kb species are present in this cell line.
In order to characterize the truncated TGF-b RII mRNA species identi®ed in the SNU-5 and SNU-668 cell lines, we examined the genomic structure of the TGF-b RII gene in each of these cell lines utilizing PCR-based methods or Southern blot analysis using an exon speci®c TGF-b RII probe. The genomic structure of the TGF-b RII gene and the nucleotide sequences of the¯anking introns for all seven exons were previously determined by PCR-based methods (Takenoshita et al., 1997) . The ®rst PCR analysis using speci®c primers for each exon demonstrated that only exons 1 and 2 of TGF-b RII in SNU-5 and exons 1, 2 and 3 in SNU-668 ( Figure 2A ) could be ampli®ed. This was con®rmed by PCR Southern blot analysis using dierent sets of primers for each exon of the TGF-b RII gene ( Figure  2B ). We tried to con®rm this ®nding by Southern blot analysis using exon-speci®c probes of exons 1, 3 and 4 of the TGF-b RII gene. Exon 3 and 4 probes failed to hybridize to the TGF-b RII gene in SNU-5, whereas only the exon 4 probe did not hybridize to the TGF-b RII gene in SNU668 in Southern blot hybridization analysis of genomic DNA ( Figure 2C ). Since exons 1, 2, and 3 encode for the extracellular domain of the TGFb RII, it is possible that the SNU-668 cell line expresses a soluble form of TGF-b RII, but the SNU-5 cell line can express only a portion of the extracellular domain of the TGF-b RII.
In order to ascertain the nature of this mutation, we generated a cDNA library from the SNU-5 cell line which expresses an abundant level of a single truncated TGF-b RII message of *1.2 kb in Northern blot analysis, and screened the cDNA library for the TGF-b RII gene sequence. A coding region of the TGF-b RII cDNA was used to screen the library. Four independent clones were isolated. Restriction fragments of the lamda phage inserts were subcloned and the resulting 1.2 kb clone (SNU-5#7 ± 4) was sequenced. The 5' sequence of the SNU-5#7 ± 4 clone corresponded to exons 1 and 2 of the TGF-b RII gene; the latter part of the sequence showed no apparent homology to TGF-b RII in the gene bank sequence (Figures 3 and 4) . The SNU-5#7 ± 4 cDNA isolated contained an open reading frame of 97 amino acid residues: Amino acids 1 ± 87 were colinear with that of the published TGF-b RII sequence, however amino acids 88 ± 97 were not related to the TGF-b RII amino acid sequence.
To address whether TGF-b responsiveness could be restored by introduction of wild type TGF-b receptors, we transiently transfected a reporter construct, p3TP-Lux, with either wild type TGF-b RI or wild type TGF-b RII, or both ( One of the essential functions of TGF-b is its role as a tumor suppressor in a variety of dierent human cell types. Expression of TGF-b RII is required for the growth inhibitory eects of TGF-bs on proliferating epithelial cells. Mutation of the TGF-b RII gene has been observed in a number of dierent human malignancies, including gastric and colon cancers, and is highly correlated with the development of TGF-b resistance (Kimchi et al., 1988; Park et al., 1994; Sun et al., 1994; Markowitz et al., 1995; Kim and Kim et al., 1996) . Transfecting human breast cancer, colon cancer, and gastric cancer as well as hepatoma cells lacking TGF-b RII with wild type TGF-b RII restores sensitivity to TGF-b and decreases tumorigenicity in transplanted breast, colon, and gastric cancer cells (Inagaki et al., 1993; Sun et al., 1994) .
In the original study describing TGF-b RII gene abnormalities in human gastric cancer, two TGF-b resistant cell lines expressed truncated TGF-b RII mRNAs when examined with Northern blotting. These smaller mRNAs are clearly dierent from another species of *3.0 kb mRNA that was detected in normal AD12 retinoblasts (Lin et al., 1992) . Southern analysis yielded a gene with gross deletion in the TGF-b RII gene (Park et al., 1994) . This suggested that a gross deletion in the TGF-b RII gene may also be involved in the escape from TGF-b growth control frequently observed in the process of carcinogenesis.
In order to characterize the nature of smaller TGF-b RII mRNAs, we analysed the genomic structure of TGF-b RII gene of SNU-5 and -668 cell lines and (Figures 3 and 4) . Considering the 567 amino acid size of normal TGF-b RII which includes 298 amino acid serine/threonine kinase domain encoded by exons 4, 5, 6, and 7, this truncated protein (97 amino acids) would be predicted to be unable to transduce a (Takenoshita et al., 1997) speci®c for each exon of the TGF-b RII gene. In SNU-5, exons 1 and 2 are ampli®ed and in SNU-668, exons 1, 2 and 3 were ampli®ed. (B) independent PCR Southern blot analysis using another set of primers for each exon of TGF-b RII (Takenoshita et al., 1997) . PCR reaction was electrophorosed on 1.5% agarose gel and transferred to a nylon ®lter paper and was hybridized with 32 P-labeled TGF-b RII cDNA probe. The result is consistent with as in (A). (C) Southern blot hybridization analysis of TGF-b type II receptor gene. Genomic DNA from human gastric cancer cell lines was digested with EcoRI, resolved by electrophoresis on 1% (w/v) agarose gels, and transferred onto nylon ®lter paper. Blots were hybridized with 32 P-labeled TGF-b RII speci®c for each exon probes (exons 1, 3 and 4), as described in`Materials and methods'. Only exon 1 was detected in SNU-5 and exons 1 and 3 in SNU-668 TGF-b signal. It has been reported that amino acids 51 ± 152, the cysteine rich region of the receptor is the core binding site (Peptin et al., 1996) . This result is consistant with our previous ®nding that this cell line is insensitive to TGF-b1 (Park et al., 1994) . On the other hand, the truncated TGF-b RII of SNU-668 which has exon 1, 2 and 3 that contains the 51 ± 152 core binding site may act as dominant negative.
Normal expression of the TGF-b RII receptor is necessary for TGF-b to exert its growth inhibitory eect. Interruption of this pathway may occur at multiple levels, transcription level, receptor mutation and signal transduction pathways (reviewed in Kim and Kim, 1996; Markowitz and Roberts, 1996) . The ®nding that the introduction of wild type TGF-b RI and wild type TGF-b RII restores TGF-b responsiveness in SNU-5 cells suggests that the remaining elements of the signal transduction pathway in this cell line are intact.
A variety of mutations in the TGF-b RII receptor have been reported. One type of mutation of the TGFb RII receptor occurs in a sequence of ten repeating adenines (polyA tract) near the transmembrane domain of the TGF-b RII receptor and the resulting downstream frameshift (one or two base deletion or insertion) leads to premature chain termination. This was the ®rst high-frequency gene mutation to be associated with the RER+phenotype in the hereditary nonpolyposis colon cancer syndrome (Markowtiz et al., 1995; Parsons et al., 1995) and also occurs at high frequency in RER+gastric carcinomas Ohue et al., 1996; Renault et al., 1996) . Another type of mutation in the TGF-b RII gene involves missense mutations usually by T-C transition, in the kinase domain of the TGF-b type II receptor Parsons et al., 1995; Lu et al., 1996) . Point mutations (G-C transversion) in the TGF-b type II receptor gene have also been identi®ed in two cases of squamous cell cancer of the head and neck (GarrigueAntar et al., 1995) . However, a high frequency of genetic alterations of the TGF-b RII gene was only identi®ed in human gastric cancers (Park et al., 1994) . Six of eight human gastric cancer cell lines examined showed genetic alterations of the TGF-b RII gene. As shown in this report, deletion of a portion of TGF-b RII gene encoding the kinase domain was only identi®ed in human gastric cancer cells, showing that truncation of the TGF-b RII gene is another alternative mechanism to inactivate the TGF-b signaling pathway.
The process of gastric carcinogenesis is considered a multistep pathway analogous to colonic carcinogenesis involving the sequential mutation of oncogenes and tumor suppressor gene. It is therefore possible to estimate the timing of key events such as loss of the TGF-b receptors by identifying the presence of accompanying mutations. A recent study of heterozygous TGF-b1 knockout mice revealed a high incidence of abnormal hyperplastic lesions in the gastric mucosa of mice harboring germ-line mutations of a single TGF-b1 allele (Biobin et al., 1996) , whereas abnormal lesions were not identi®ed in any other organ system studied. The presence of potentially preneoplastic lesions in the stomach alone in association with allelic loss of TGF-b1 suggests that the stomach alone may be uniquely vulnerable to the development of malignancy in response to defects in the TGF-b signaling pathway. Recently, we have shown that patients with H. pylori-associated gastritis all were associated with markedly reduced levels of TGF-b1 in their gastric tissues when compared with normal control and non-H. pylori associated gastritis, (Hahm et al. in press) . The decreases in gastric mucosal TGFb1 were more profound in H. pylori-associated duodenal ulcer patients than H. pylori-associated gastric ulcer patients. There was a signi®cant correlation between the severity of the degree of in¯ammation by H. pylori infection and decreased levels of gastric mucosal TGF-b1. These results suggest that H. pylori infection suppresses gastric mucosal TGF-b1 expression and this can lead to increased susceptibility to in¯ammation/ulceration.
Normal expression of the TGF-b RII is clearly necessary for TGF-b to exert its growth inhibitory eects. The characterization of high-frequency mutations in the TGF-b RII gene may lead to unrestrained clonal growth in human cancers including gastric cancer, suggesting that TGF-b RII is an important tumor suppressor gene.
Materials and methods

Cell lines and cell culture
Human gastric cancer cell lines, SNU-5, SNU-16 and SNU-668, established from gastric carcinomas of individual patients were generously supplied by Dr Jae-Gahb Park (Cancer Research Center, Seoul National University College of Medicine) and were maintained as previously described (Park et al., 1994 (Park et al., , 1997 . Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum.
Northern blot analysis
Total RNA was isolated with guanidium isothiocyanate/ phenol/chloroform (Chomaczynski and Sacchi, 1987) . formaldehyde, transferred to a nylon membrane (Nytran; Schleicher and Schunell, Keene), and cross-linked using a UV Stratalinker (Stratagene, La Jolla, CA, USA). Blots were hybridized in 50% formamide/ 56SSPE/ 0.5% SDS/ 56 Denhardt's solution at 428C for 20 h. 32 P-labeled probes were prepared from human TGF-b RII cDNA (ref. Lin et al., 1992 ; a gift from Dr Robert A Weinberg, Massachusetts Institute of Technology, Cambridge, MA, USA) and b-actin cDNA fragments as templates using Prime-It RmT kit (Stratagene, La Jolla, CA, USA).
PCR analysis
PCR analysis of genomic DNA of gastric cancer cell lines was performed with two independent sets of primers (Lu et al., 1996; Takenoshita et al., 1997) designed to amplify individual exons of TGF-b RII gene according to conditions previously reported (Lu et al., 1996; Takenoshita et al., 1997) . PCR Southern blot analysis was carried out with probes from human TGF-b RII cDNA (Lin et al., 1992) .
Southern blot analysis
To further con®rm the exon-speci®c gene deletion in gastric cancer cells, Southern blot analysis of genomic DNA was also carried out. Ten mg of genomic DNA was digested with EcoRI (40 units; Boehringer Mannheim, Mannheim, Germany) overnight. Restricted DNA was electrophorosed on a 1% agarose gel and transferred to a positive charged nylon membrane (Nytran-plus; Schleicher and Schuell, Keene, NH, USA). Blots were hybridized with random-primed labeled probes in 50% formamide/66SSC/ 1% SDS at 428C for 20 h. Probes were speci®c to exon 1, 3 or 4 of TGF-b RII. Templates for probes were prepared by PCR ampli®cation with primers as described (Lu et al., 1996) and subsequent subcloning.
Cloning of TGF-b RII receptor cDNA of SNU-5 A cDNA library was generated in ZAP Express vector (Stratagen, La Jolla, CA, USA) from size-fractionated cDNA made from the SNU-5 cell line, per manufacturer's instruction. In brief, we constructed a size-selected cDNA library from SNU-5 cells, and after linking adaptors to the ends, inserted the cDNAs into the vector. After transfection into E. coli, pools of independent clones were separated and grown on NZY plates and screened with Southern blot analysis. This library was screened at high stringency with a probe for TGF-b RII cDNA (Lin et al., 1992) . Selected clones were recultured to get plasmid by in vivo excision per manufacturer's protocol. The dideoxy chain termination method was used to sequence double-stranded DNA of cloned plasmids utilizing reagents from Sequenase (United States Biochemicals, Cleveland, Ohio).
Transient transfection and luciferase assay SNU-5 cells were seeded in 6 well plates at 1.6610 6 cells/ wells as triplicates and transiently co-transfected with the p3TP-Lux reporter that contains multiple TGF-b response elements (Wrana et al., 1992) and a b-gal reporter with either wild type TGF-b RI DNAs (1 mg) alone or with wild type TGF-b RII (1 mg) or both, using Lipofectin (Life Technologies, Inc., Gaithersburg, MD, USA). After 4 h, complete medium was added, and cells were incubated for an additional 12 h. Cells were treated with 10 ng/ml TGF-b1 for an additional 48 h. Luciferase activity was determined in the cell lysate using an assay kit (Analytic Luminescence Lab, Ann Arbor, MI, USA), and a Dynatech Laboratories ML3000 microtiter plate luminometer (Dynatech Laboratories, Chantilly, VA, USA). Activities were normalized on the basis of b-galactosidase expression from pSV-b-galactosidase in all luciferase reporter experiments.
Abbreviations TGF-b, transforming growth factor b; RI, receptor type I; RII, receptor type II; WT, wild type.
